Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
Northern Trust Corp Has $3.45 Million Stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
09:18am, Tuesday, 23'rd Nov 2021 Transcript Daily
Northern Trust Corp grew its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 389.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,108,226 shares of the companys stock after purchasing an additional 2,472,687 shares during the period. Northern Trust Corp owned about 0.87% []
FDA Clears Tonix Pharma's Human Trial With Intranasal Oxytocin For Migraine
08:40am, Tuesday, 23'rd Nov 2021
The FDA has signed off Tonix Pharmaceuticals Holding Corp's (NASDAQ: TNXP) Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine. TNX-1900 is intranasal po
Tonix Pharmaceuticals (TNXP) Stock: Why The Price Surged Today
06:06am, Tuesday, 23'rd Nov 2021
The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased by over 25% pre-market today. This is why it happened.
Tonix Pharma rises after announcing publication of study on COVID-19 antiviral
09:52pm, Monday, 22'nd Nov 2021 Seeking Alpha
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
09:05pm, Monday, 22'nd Nov 2021 GlobeNewswire Inc.
Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir Early Studies in vitro Show that TNX-3500 is
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
09:05pm, Monday, 22'nd Nov 2021 Intrado Digital Media
Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir
Why To Invest In Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Stock?
06:00pm, Tuesday, 16'th Nov 2021 Marketing Sentinel
In the latest trading session, 4.55 million Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares changed hands as the companys beta touched 1.16. With the companys most recent per share price at $0.54 changed hands at -$0.04 or -6.11% at last look, the market valuation stands at $253.32M. TNXPs current price is a discount, trading about -292.59% Why To Invest In Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Stock? Read More »
Why Tonix Pharmaceuticals Holding Zoomed Higher Today
11:21pm, Monday, 15'th Nov 2021 The Motley Fool
The company secures a potentially crucial piece of intellectual property.
Why Tonix Pharmaceuticals Holding Zoomed Higher Today
06:21pm, Monday, 15'th Nov 2021
The company secures a potentially crucial piece of intellectual property.
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
10:30am, Sunday, 31'st Oct 2021
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Info
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland
07:00am, Friday, 15'th Oct 2021
Internal R&D Capabilities Expected to Support U.S. Pandemic Preparedness with Accelerated Discovery and Development of Vaccines and Antivirals Against COVID-19 and Other Infectious Diseases
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
07:00am, Thursday, 07'th Oct 2021
CHATHAM, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.
Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland
07:00am, Monday, 04'th Oct 2021
R&D Center is Expected to Accelerate Internal Discovery and Development of Vaccines and Antiviral Drugs Against COVID-19, its Variants and Other Infectious Diseases
Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
07:00am, Thursday, 23'rd Sep 2021
Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immunity Against SARS-CoV-2
Tonix Pharma Shares FDA Response For COVID-19 Vaccine Candidate Human Study
09:44am, Monday, 13'th Sep 2021
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vac
